Abstract

Introduction
Alloimmunisation against the D antigen in pregnant RhD-negative women is preventable using anti-D immune prophylaxis1. A combination of antenatal and postnatal anti-D administration has dramatically reduced alloimmunisation of RhD negative women from 16% to 0.3%1,2. Analysis of cell-free foetal DNA (cffDNA) circulating in maternal plasma facilitates non-invasive antenatal testing of the foetal RhD genotype at an early gestational age3,4. Knowledge of the foetal RhD type allows targeted use of antenatal prophylaxis, avoiding unnecessary treatment of RhD-negative women who are carrying a RhD-negative foetus, and are thus at no risk of immunisation. [...]

Downloads

Authors

Frederik B. Clausen - Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Angela N. Barrett - Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore

Grethe R. Krog - Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Kirstin Finning - International Blood Group Reference Laboratory, NHS Blood and Transplant, Bristol, United Kingdom

Morten H. Dziegiel - Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

  • Abstract viewed - 3 times
  • PDF downloaded - 1 times